CDMO: Contract Manufacturing

Cabazitaxel EVER Pharma is provided as a single vial, ready to dilute formulation and is available in vial sizes covering the common range of patient specifi c doses for economy and convenience Cabazitaxel is a third-generation antineoplastic taxane and was the fi rst therapy to show a survival benefi t f...

EVER is a leader in pharmaceutical development


Our end-to-end service covers every aspect of pharmaceutical development, from API selection to final process validation and quality assurance, with the highest level of expertise.

With ‘state of the art’ labs in Unterach ...

Our products include: Atosiban Cabazitaxel Cebrium(R) Cerebrolysin(R) Dacepton(R) Dexmedetomidine Docetaxel Fulvestrant MemoProve(R) Oxytocin Paclitaxel Pemetrexed Tachyben(R) Terlipressin

Our products include:  • Atosiban • Cabazitaxel • Cerbrium • Cerebrolysin • Dacepton/Apomorphine • Dexemedetomidine • Docetaxel • Fulvestrant • MemoProve • Oxytocin • Paclitaxel • Pemetrexed • Tachyben • Terlipressin • Trabectedin • Eribulin

Pemetrexed is an antineoplastic chemotherapy drug. It is used in the treatment of malignant mesothelioma and locally advanced or metastatic nonsquamous non-small cell lung cancer. - Available as a ready to dilute liquid formulation - does not require reconstitution from powder saving time and costs. It can...

- Ready to use product - for immediate use without reconstitution - Available in vials - safer and more convenient than ampoules - 5ml and new 10ml presentation covering initial and maintenance dose ranges - Additional indication - for Hepato-renal syndrome type I

- Available in 2 presentations – providing greater flexibility and convenience when preparing patient specific doses - All vial sizes come in CytoWrap® – for safer handling and transportation Description: Trabectedin is an antineoplastic chemotherapy drug. It is indicated as a monotherapy for the treatme...

Azacitidine is a cytotoxic hypomethylating chemical analogue of cytidine used in the treatment of myelodysplastic syndromes.

Azacitidine EVER Pharma is available in both the standard 100 mg vial size and a new 150 mg vial size aligned to the most common patient doses to minimize waste...

Bortezomib is a protease inhibitor indicated for the treatment of progressive or untreated multiple myeloma, and mantle cell lymphoma.

Bortezomib EVER Pharma is provided as a ready to useformulation for subcutaneous injection (SC), and afterdilution for intravenous injection.

Cabazitaxel is a third-generation antineoplastic taxane and was the fi rst therapy to show a survival benefi t for the treatment of patients with docetaxel-refractory mCRPC.

Cabazitaxel EVER Pharma is provided as a single vial, ready to dilute formulation and is available in vial sizes&nbs...

Dexmedetomidine is a highly selective alpha-2 adrenergic receptor notable for its ability to provide sedation without the risk of respiratory depression.
The first Dexmedetomidine in Europe indicated for both ICU and procedural sedation.

The first Fulvestrant in Europe approved for storageat room temperature.

EVER Pharma announces the EU-wide marketing authorization of Trabectedin (in 0.25MG and 1MG vial sizes) for the treatment of advanced soft tissue sarcoma and ovarian cancer

EVER Pharma's products include: Atosiban --  7.5 mg/ml Solution for Injection/InfusionAzacitidine -- 25 mg/ml Powder for Suspension for InjectionCabazitaxel -- 10 mg/ml - Solution for InfusionCerebrolysin® -- 215.2 mg/ml - Solution for Infusion Concentrate for Solution for InfusionDacepton (Apomorphine) -- 5 mg/ml & 10 mg/ml -  Solution for Injection/InfusionDexmedetomidine -- 100 µg/ml - Concentrate for Solution for InfusionDocetaxel -- 20 mg/ml - Concentrate for injectionFulvestrant -- 50 mg/ml - Ready to use pre-filled syringeOxytocin -- 5 IU/ml & 10 IU/ml - Solution for Injection/InfusionPaclitaxel-- 6 mg/ml - Concentrate for InjectionPemetrexed -- 25 mg/ml - Concentrate for Solution for InfusionTerlipressin -- 0.17 mg/ml - Solution for Injection/Infusion

EVER Pharma Expands Operations with Opening of New Manufacturing Facility in Jena, Germany

Contract Manufacturing Overview

EVER Pharma has announced the approval of Testosterone Undecanoate in the European Union for the treatment of male hypogonadism. 

Overview on EVER's contract development services

EVER Pharma, a fully integrated specialty pharmaceuticals company, is pleased toannounce the approval of Testosterone Enantate in the European Union for thetreatment of male hypogonadism. This condition, characterized by insufficienttestosterone production, affecting up to 10% of men globally and 40% of men aged 45.

EVER Pharma's products include: Atosiban --  7.5 mg/ml Solution for Injection/InfusionAzacitidine -- 25 mg/ml Powder for Suspension for InjectionCabazitaxel -- 10 mg/ml - Solution for InfusionCerebrolysin® -- 215.2 mg/ml - Solution for Infusion Concentrate for Solution for InfusionDacepton (Apomorphine) -- 5 mg/ml & 10 mg/ml -  Solution for Injection/InfusionDexmedetomidine -- 100 µg/ml - Concentrate for Solution for InfusionDocetaxel -- 20 mg/ml - Concentrate for injectionFulvestrant -- 50 mg/ml - Ready to use pre-filled syringeOxytocin -- 5 IU/ml & 10 IU/ml - Solution for Injection/InfusionPaclitaxel-- 6 mg/ml - Concentrate for InjectionPemetrexed -- 25 mg/ml - Concentrate for Solution for InfusionTerlipressin -- 0.17 mg/ml - Solution for Injection/Infusion

EVER Pharma, a fully integrated specialty pharmaceuticals company, announced the approval of Eribulin in the European Union. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.

45mg/4.5ml + 50mg/5.0ml + 60mg/6ml

EVER Pharma is pleased to announce EU-wide approval of Bortezomib for the treatment of patients with multiple myeloma and mantle cell lymphoma

0.25mg + 1mg

PFS - 250mg/5ml

Vials + Ampoules: 200µg/2ml + 400µg/4ml + 1000µg/10ml

1mg/5ml + 2mg/10ml

6.75mg/0.9ml + 37.5/5ml + 75mg/10ml

2.5mg/1ml + 3.5mg/1.4ml

100mg/4ml + 500mg/20ml + 1000mg/40ml